Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
== Suicide == Since 2013, the National Suicide Observatory has published data on suicide trends in France. Sociological and demographic factors influence the incidence and outcome of suicide across genders.
In May 2023, Lula and Rosângela travelled to the United Kingdom to attend the coronation of Charles III and Camilla and had a separate meeting with the King. Lula also met with the UK's Prime Minister Rishi Sunak, who announced his country was donating £80 million (BRL 500 million) to the Amazon Fund initiative, run by Brazil. During his trip, Lula called for the release of WikiLeaks founder Julian Assange, adding that "we talk about freedom of speech [but] the guy is in prison because he denounced wrongdoing" and "it is an embarrassment that a journalist who denounced trickery by one state against another is arrested, condemned to die in jail and we do nothing to free him. It's a crazy thing". Lula urged to create an international media movement to lobby for Assange's release.
=== Phase 2 === ASP-8062 – GABAB receptor positive allosteric modulator – alcoholism BP-1.3656B (BP-1.3656; BP1.3656B; BP13656) – histamine H3 receptor antagonist – alcoholism BP-1.4979 (BP-1.4979; BP-14979; BP14979) – dopamine D3 receptor partial agonist – smoking withdrawal Brenipatide (LY-3537031) – glucagon-like peptide-1 (GLP-1) receptor agonist, gastric inhibitory polypeptide (GIP) receptor agonist – smoking withdrawal Buprenorphine sublingual ethanol-free (CHF-6563; CHF6563) – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor antagonist, nociceptin receptor agonist – opioid-related disorders Buprenorphine/naloxone (naloxone/buprenorphine) – combination of buprenorphine (non-selective opioid receptor modulator) and naloxone (orally/sublingually inactive opioid receptor antagonist) – opioid-related disorders Bupropion/dextromethorphan (bupropion/DXM; Auvelity; AXS-05) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), nicotinic acetylcholine receptor antagonist, CYP2D6 inhibitor) and dextromethorphan (DXM) (NMDA receptor antagonist, serotonin reuptake inhibitor, sigma receptor agonist, other actions) – smoking withdrawal Bupropion/naltrexone (Contrave; CX-101; Mysimba; naltrexone/bupropion; NB32) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), nicotinic acetylcholine receptor antagonist) and naltrexone (opioid receptor antagonist) – smoking withdrawal Cannabidiol (CBD; A-1002-N5S; Nantheia) – cannabinoid/various actions – opioid-related disorders, smoking withdrawal Cannabidiol (CBD; Epidiolex; Epidyolex; Epidiolexa; GW-42003; GWP-42003; GWP-42003-P; JZP-926) – cannabinoid/various actions – heroin-related disorders, opioid-related disorders Centanafadine (CTN-SR; EB-1020) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – smoking withdrawal Cocaine esterase (RBP-8000; TNX-1300) – enzyme replacement – cocaine-related disorders Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (various actions) and prazosin (α1-adrenergic receptor antagonist) – alcoholism Devextinetug (anti-methamphetamine chimeric monoclonal antibody; Ch-mAb7F9; IXT-m200; METH-mAb) – immunomodulator (monocloncal antibody against methamphetamine) – substance-related disorders F-652 (IL-22 IgG2 Fusion Protein; IL-22 IgG2-Fc; rhIL-22 dimer) – interleukin, immunoglobulin Fc fragment, recombinant fusion protein, anti-inflammatory, hepatoprotectant – alcoholism and alcoholic hepatitis Ibudilast (AV-411; Eyevinal; Ibinal; KC-404; Ketas; MN-166; Pinatos) – phosphodiesterase PDE4 inhibitor, toll-like receptor 4 (TLR4) antagonist – alcoholism, opioid-related disorders, substance-related disorders Liraglutide (LATIN-T1D; NN-2211; NN-9211; NN-8022; NNC-90-1170; Saxenda; Victoza) – glucagon-like peptide-1 (GLP-1) receptor agonist – smoking withdrawal Lixosicone (AEF-0117; AEF0117) – biased cannabinoid CB1 receptor negative allosteric modulator (pregnenolone derivative) – substance-related disorders Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist – alcoholism Mazdutide (IBI-362; LY-3305677; OXM-3) – glucagon-like peptide-1 (GLP-1) receptor agonist, glucagon receptor agonist – alcoholism Mebufotenin benzoate (5-MeO-DMT; BPL-002; BPL-003) – non-selective serotonin receptor agonist, serotonin 5-HT1A and 5-HT2A receptor agonist, serotonergic psychedelic – alcoholism Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABAA receptor positive allosteric modulator) – cocaine-related disorders Midomafetamine (MDMA) – serotonin–norepinephrine–dopamine releasing agent (SNDRA), serotonin 5-HT2 receptor agonist, entactogen – alcoholism Mifepristone (C-1073; Corlux; Corluxin; Korlym; Mifegyne; Mifeprex; RU-38486; RU-486) – glucocorticoid, progesterone, and androgen receptor antagonist – alcoholism Miricorilant (CORT-118335) – glucocorticoid and mineralocorticoid receptor antagonist – alcoholism Nadolol (INV-102; INV102) – non-selective beta blocker (β1- and β2 adrenergic receptor agonist) – smoking withdrawal Neboglamine (nebostinel; CR-2249; XY-2401) – ionotropic glutamate glycine-gated NMDA receptor agonist – cocaine-related disorders NNC0194-0499 (NN-9500; NN-9499; NNC-0194-0499) – fibroblast growth factor (FGF) receptor agonist – substance-related disorders NS-2359 (GSK-372475) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – cocaine-related disorders OMS-405 (OMS405) – PPARγ agonist – opioid-related disorders, smoking withdrawal Pemvidutide (ALT-801- Altimmune; SP-1373; VPD-107) – glucagon-like peptide-1 (GLP-1) receptor agonists, glucagon receptor agonist – alcoholism Psilocybin (SYNP-101; synthetic psilocybin) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – alcoholism Selonabant (ANEB-001; V-24343) – cannabinoid CB1 receptor antagonist – substance-related disorders Sunobinop (IMB-115; IT-1315; RSC117957; S-117957; V-117957) – nociceptin receptor agonist – alcoholism TA-CD (TA-CD; TA-CD09) – immunostimulant (cocaine vaccine) – cocaine-related disorders Zabaglurant (Heptares 25; HTL-0014242; HTL14242; TMP-301) – metabotropic glutamate mGlu5 receptor negative allosteric modulator – alcoholism Zolunicant (18-methoxycoronaridine; 18-MC; MM-110) – α3β4 nicotinic acetylcholine receptor antagonist – opioid-related disorders
Since 1921, the Toronto Transit Commission (TTC) gradually expanded its public transportation network to Scarborough. Today, it operates bus and rapid transit routes in the district. Line 2 Bloor–Danforth has three subway stations in Scarborough: Victoria Park, Warden, and Kennedy, the current eastern terminus. In 1985, the Government of Ontario opened the Scarborough RT, an above-ground light metro line that operated between Kennedy station at its west and McCowan Road at its east. In 2023, the line shut down permanently due to aging Infrastructure which also caused a derailment earlier that year. Construction of an extension of Line 2 further east into Scarborough started in June 2021 and is expected to be complete around 2030. The line will be extended 7.8 kilometres from Kennedy station with stations at McCowan Road-Lawrence Avenue, Scarborough Centre, and McCowan Road-Sheppard Avenue. Opened in February 2026, Line 5 Eglinton is a light rail line with its eastern terminus at Kennedy station. The City of Toronto is also proposing another light rail line known as the Eglinton East LRT that is planned to operate from Kennedy station to the University of Toronto Scarborough. Seven rail stations also provide access to two commuter rail lines operated by GO Transit. The Lakeshore East line runs across the south end of the district with Rouge Hill GO Station, Guildwood GO Station, Eglinton GO Station, and Scarborough GO Station running from east to west.
== Israeli rationale == Since the establishment of the Islamic Republic of Iran in 1979, the regime has repeatedly called for Israel's destruction, which, in combination with Iran's alleged nuclear aspirations and its sponsorship of militias, has led Israel to view Iran as an existential threat. Israeli officials have viewed Iran's ballistic missile program and nuclear capabilities as an existential threat. US Senator Mark Warner has stated that Iran's ballistic missiles are not a threat to the US, but that they are to Israel. Benjamin Netanyahu, the Prime Minister of Israel, had wanted to attack Iran for decades, and made plans for such an attack in an earlier term as prime minister, more than a decade earlier. Trump getting into office provided Netanyahu with a good opportunity to pressure the US to attack Iran, especially after its proxies such as Hezbollah are not as powerful as they used to be. Throughout the war, Israeli strategy has reflected the aim of eliminating Iran as a rival regional power. Israeli strikes have targeted Iran's political elites broadly across differing factions and currents, undermining the possibility of regime change, while Israeli officials and intelligence agencies have also incited and backed ethnic separatist causes which threaten Iran's internal stability.
Sources: en.wikipedia.org
=== 2. Periodontal ligament === The periodontal ligament is a specialized, vascular, and cellular connective tissue occupying the space between the cementum of the tooth root and the alveolar bone socket. It is primarily composed of dense collagen fiber bundles, known as Sharpey's fibers, which anchor the tooth to the surrounding alveolar bone. Functionally, the periodontal ligament acts as a shock absorber during mastication, provides proprioceptive sensory input, and contributes to the nutritional and reparative capacity of the periodontal tissues. In periodontitis, progressive destruction of periodontal ligament fibers occurs in association with apical migration of the junctional epithelium, resulting in increased tooth mobility.
LCFAs are important to cells as they can act as stored sources of energy, signaling molecules, and as building blocks for cell membranes. Transporting these LCFAs through the cell so that they may serve these many roles is thus imperative for the cell to do. The carnitine shuttle evolved as a way for cells to be able transport LCFAs to the many places they are needed for these roles. The LCFA's are synthesized, or absorbed. Carnitine is similarly either synthesized, or absorbed. The acyl-CoA comes from Acyl-CoA synthetase. The shuttle's mechanism is as follows:
Initially, not all cigarette smokers inhaled the smoke produced by cigarettes due to its high alkalinity levels. Starting in the 1930s, the tobacco industry began to conduct advertising campaigns encouraging the inhaling of cigarette smoke. However, Helmuth von Moltke noticed in the 1830s that Ottomans (and he himself) inhaled the Turkish tobacco and Latakia from their pipes (both are initially sun-cured, acidic leaf varieties).
=== Serum albumin purification === Affinity purification of albumin and macroglobulin contamination is helpful in removing excess albumin and α2-macroglobulin contamination, when performing mass spectrometry. In affinity purification of serum albumin, the stationary used for collecting or attracting serum proteins can be Cibacron Blue-Sepharose. Then the serum proteins can be eluted from the adsorbent with a buffer containing thiocyanate (SCN−).
Sources: en.wikipedia.org
==== Opposition to the Patriot Act ==== Sanders was a consistent critic of the Patriot Act. As a member of the House, he voted against the original Patriot Act legislation. After its 357–66 passage in the House, he sponsored and voted for several subsequent amendments and acts attempting to curtail its effects and voted against each reauthorization. In June 2005, he proposed an amendment to limit Patriot Act provisions that allow the government to obtain individuals' library and book-buying records. The amendment passed the House by a bipartisan majority but was removed on November 4 of that year in House–Senate negotiations and never became law.
== External links == Clegg, Simon. "Surface tension calculator for aqueous solutions". www.aim.env.uea.ac.uk. University of East Anglia. Retrieved 26 August 2026. Clegg, Simon. "Densities of H+ - NH+4 - Na+ - SO2−4 - NO−3 - Cl− - H2O". www.aim.env.uea.ac.uk. University of East Anglia. Retrieved 26 August 2026.
R = universal gas constant m = number of occupied lattice sites per molecule (for polymer solutions m1 is approximately equal to the degree of polymerization and m2=1) φ = volume fraction of the polymer and the solvent, respectively χ = interaction parameter A consequence of the Flory-Huggins theory is, for instance, that the UCST (if it exists) increases and shifts into the solvent-rich region when the molar mass of the polymer increases. Whether a polymer shows LCST and/or UCST behavior can be derived from the temperature-dependence of the interaction parameter (see figure). The interaction parameter not only comprises enthalpic contributions but also the non-ideal entropy of mixing, which again consists of many individual contributions (e.g., the strong hydrophobic effect in aqueous solutions). For these reasons, classical Flory-Huggins theory cannot provide much insight into the molecular origin of miscibility gaps.
== Further reading == Sigel, Roland K. O.; Skilandat, Miriam; Sigel, Astrid; Operschall, Bert P.; Sigel, Helmut (2013). "Chapter 8. Complex formation of cadmium with sugar residues, nucleobases, phosphates, nucleotides and nucleic acids". In Sigel, Astrid; Sigel, Helmut; Sigel, Roland K. O. (eds.). Cadmium: From Toxicology to Essentiality (PDF). Metal Ions in Life Sciences. Vol. 11. Springer. pp. 191–274. doi:10.1007/978-94-007-5179-8_8. ISBN 978-94-007-5178-1. PMID 23430775. Sóvágó, Imre; Várnagy, Katalin (2013). "Chapter 9. Cadmium(II) complexes of amino acids and peptides". In Sigel, Astrid; Sigel, Helmut; Sigel, Roland K. O. (eds.). Cadmium: From Toxicology to Essentiality. Metal Ions in Life Sciences. Vol. 11. Springer. pp. 275–302. doi:10.1007/978-94-007-5179-8_9. ISBN 978-94-007-5178-1. PMID 23430776. Yatsimirsky, Konstantin Borisovich; Vasilyev, Vladimir Pavlovich (1960). Instability Constants of Complex Compounds. Translated by Patterson, D. A. OUP.
Furthermore, sample processing for downstream mass spectrometry (MS) analysis is much more intensive than in NMR application, and results in the destruction of the original sample (via trypsin digestion). Following identification and quantification of metabolites in individual patient samples, NMR and mass spectrometry (MS) output is compiled into a dataset. These datasets include information on the identity and levels of individual metabolites detected within processed samples, as well as characteristics of each metabolite during the detection process (e.g. mass-to-charge ratios for mass spectrometry (MS)-based analysis). Multiple datasets can be created and compiled into large databases for individual patients in order to monitor varying metabolic profiles over a treatment course (i.e. pre- and post-treatment profiles). Each database is then processed through a type of informatics platform with software designed to characterize and analyze the data to generate an overall metabolic profile for the patient. To generate this overall profile, computational programs are designed to:
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.